SOURCE GT Apeiron Therapeutics View original content:http://www.prnewswire.com/news-releases/gt-apeiron-therapeutics-strengthens-advisory-board-301269954.html Source
About GT Apeiron Therapeutics The Advisory Board will help support the advancement of Company’s differentiated portfolio, including next generation selective CDK inhibitors for oncology.
GT Apeiron Therapeutics is a Shanghai-headquartered biotechnology platform utilizing artificial intelligence and state-of-the-art technologies for drug discovery. For more information please visit: http://www.apeiron-bio.com/ Dr. Honggang Bi is currently Senior Vice President, Drug Development Head APAC, and General Manager China at Covance by Labcorp, a proven global leader and expert in preclinical development, clinical trial testing and clinical trial management. Dr. Bi brings more than 28 years of industry experience as he held R&D leadership roles at companies such as SmithKline Beecham, Parke-Davis, Pfizer, and Frontage, prior to joining Covance.
The News Highlights
- GT Apeiron Therapeutics strengthens advisory board
- Check the latest Gaming news updates and information about games.
- Please share this news with your friends and family to support us your one share helps us a lot.
- Follow us on Facebook and Twitter, for similar updates.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week